Reid Laurence purchased $23K of MGX
Reid Laurence purchased 20,000 shares of Metagenomi Therapeutics, Inc. (MGX) at an average of $1.17 ($1.17–$1.18) across 2 trades on 2026-09-09.
How this was made
The 30-second read
Why it matters
The transaction is modest and unlikely to move the stock, but it provides a data point for tracking insider sentiment.
Market read
Low relevance; a routine insider purchase with minimal market impact.
What to watch
Potential upcoming clinical data or partnership announcements could give context to the purchase.
Background
Form 4 disclosures are primary sources for insider transactions. This filing reports a director's purchase of MGX shares.
Ticker impact
Director Reid Laurence bought 20,000 shares for $23,401, a Form 4 filing disclosed today.
Minimal impact; likely no immediate price movement.
Purchase amount is modest ($23K) and unlikely to affect market perception.
Market effects
None; isolated insider transaction.
None; company is US‑listed biotech.
None
Counterpoint
Even small insider buys can precede larger moves; monitor for follow‑on activity.
Key entities
- CompanyMetagenomi Therapeutics, Inc.
Biotech firm developing microbiome‑based therapies, ticker MGX.
- PersonReid Laurence
Director of Metagenomi Therapeutics.
